Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon‐γ: abrogation of immune response defect to a T‐cell‐dependent antigen
- 1 April 1996
- journal article
- Published by Wiley in Immunology
- Vol. 87 (4) , 519-527
- https://doi.org/10.1046/j.1365-2567.1996.516576.x
Abstract
The experiments presented here were performed to see whether the level of expression of major histocompatibility complex (MHC) class II antigen (Ia antigen) on dendritic cells, one of the most critical antigen presenting cells (APC), influences the humoral immune response in hepatitis B virus (HBV) transgenic mice. We have reported that transgenic mice had a low responsiveness in specific antibody production to keyhole limpet haemocyanin (KLH), a T-cell dependent, HBV-unrelated antigen compared with the age, sex, and major histocompatibility-matched normal mice, due to a significantly lower T-cell stimulatory capacity of transgenic mice-derived dendritic cells, possibly as a result of significantly lower level of Ia antigen. Immunohistochemical staining has shown that treatment of transgenic mice with mouse recombinant interferon-gamma (IFN-gamma), daily for six consecutive days resulted in an increased expression of Ia antigen on splenic dendritic cells. Again, flow cytometric analyses have further confirmed the significant increase in the expression of Ia antigen on dendritic cells, isolated from transgenic mice treated with IFN-gamma compared with the same from the untreated or phosphate-buffered saline (PBS)-treated transgenic mice. Transgenic mice immunized with two optimum doses of KLH (5 micrograms/mouse) could not produce anti-KLH antibodies in sera, but injecting transgenic mice with the same doses of KLH together with IFN-gamma resulted in the production of anti-KLH antibodies in sera. Again, KLH-primed normal mice-derived T/B lymphocytes produced anti-KLH antibody, when cultured with dendritic cells from IFN-gamma-treated transgenic mice expressing a higher level of Ia antigen, but not with the same from PBS-treated or untreated transgenic mice. Treatment of transgenic mice with IFN-gamma resulted in a reduced level of hepatitis B virus (HBV) DNA in liver and in sera. These experiments have shown that the level of expression of Ia antigen on dendritic cells is a critical factor for its APC capability and its modulation of IFN-gamma may be used for immune therapy in HBV carriers.Keywords
This publication has 26 references indexed in Scilit:
- The serology of chronic hepatitis B infection revisited.Journal of Clinical Investigation, 1993
- The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymusCellular Immunology, 1989
- Expression and replication of hepatitis B virus genome in transgenic mice.Proceedings of the National Academy of Sciences, 1989
- LymphokinesNew England Journal of Medicine, 1987
- Impaired Antibody Synthesis in Patients With Chronic Hepatitis B InfectionHepatology, 1986
- Differential expression of Ia and Ia-associated invariant chain in mouse tissues after in vivo treatment with IFN-gamma.The Journal of Immunology, 1986
- Resting and sensitized T lymphocytes exhibit distinct stimulatory (antigen-presenting cell) requirements for growth and lymphokine release.The Journal of Experimental Medicine, 1984
- Pure interferon gamma enhances class II HLA antigens on human monocyte cell linesEuropean Journal of Immunology, 1984
- Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers.Journal of Clinical Investigation, 1983
- In vitro antigen-induced, antigen-specific antibody production in man. Specific and polyclonal components, kinetics, and cellular requirements.The Journal of Experimental Medicine, 1981